These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18932257)

  • 1. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
    Borthakur G; Kantarjian H; Wang X; Plunkett WK; Gandhi VV; Faderl S; Garcia-Manero G; Ravandi F; Pierce S; Estey EH
    Cancer; 2008 Dec; 113(11):3181-5. PubMed ID: 18932257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in patients with core-binding factor acute myeloid leukemia.
    Solis EC
    Curr Oncol Rep; 2011 Oct; 13(5):359-60. PubMed ID: 21755276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
    Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
    J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
    Qian SX; Wu HX; Hong M; Lu H; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1577-81. PubMed ID: 20030951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y; Turzanski J; Pallis M; Russell NH
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
    Estey EH; Thall PF; Cortes JE; Giles FJ; O'Brien S; Pierce SA; Wang X; Kantarjian HM; Beran M
    Blood; 2001 Dec; 98(13):3575-83. PubMed ID: 11739159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
    Borthakur G; Ravandi F; Patel K; Wang X; Kadia T; DiNardo C; Garcia-Manero G; Pemmaraju N; Jabbour EJ; Takahashi K; Ohanian M; Daver N; Alvarado Y; Brandt M; Pierce S; Kantarjian H
    Am J Hematol; 2022 Nov; 97(11):1427-1434. PubMed ID: 36053747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Ossenkoppele GJ; Graveland WJ; Sonneveld P; Daenen SM; Biesma DH; Verdonck LF; Schaafsma MR; Westveer PH; Peters GJ; Noordhuis P; Muus P; Selleslag D; van der Holt B; Delforge M; Löwenberg B; Verhoef GE;
    Blood; 2004 Apr; 103(8):2908-13. PubMed ID: 15070662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Montillo M; Ricci F; Tedeschi A; Cafro AM; Nosari AM; Nichelatti M; Marbello L; Morra E
    Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.